ArticleFrontiers in endocrinology2025
Association between exposure to terpene compounds and risk of metabolic syndrome: exploring the potential mediating role of inflammatory response.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Terpenes are potentially harmful substances that are associated with endocrine disruption due to their ability to produce oxidizers, aldehydes, and secondary aerosol particles. However, the exact association between terpenoids and metabolic syndrome remains unclear. Objective: This study aims to examine the relationship between individual and mixed exposure to terpene compounds and the risk of developing metabolic syndrome. Methods: We utilized data from the NHANES 2013-2014 cycle, including 1,135 participants. Multiple regression models, Bayesian kernel regression (BKMR), and quantile g calculation (QGC) were employed to assess the association between individual and mixed terpene exposure and metabolic syndrome. Additionally, a mediation analysis was performed to explore potential biological pathways mediated by inflammation, using the Advanced Cancer Inflammation Index as a metric. Results: The regression analysis indicated a positive association between exposure to limonene and metabolic syndrome (OR (95%):1.74(1.17, 2.57), p=0.005). The BKMR regression and the QGC model showed a positive association between exposure to mixed terpenes and the increased risk of metabolic syndrome (p=0.001). Subgroup analyses within the BKMR revealed significant positive trends among males, individuals under 60, and the overweight groups. Furthermore, exposure to mixed terpenes exhibited positive trends with lower HDL levels(p<0.000). The Advanced Cancer Inflammation Index was identified as a potential mediator of the positive correlation between α-pinene, β-pinene, and metabolic syndrome. Conclusions: This study suggests that exposure to both individual and mixed terpenes may increase risk of developing metabolic syndrome. However, further longitudinal studies are imperative to establish causality between terpene compounds and the risk of metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.